Hepatitis c, chronic Trials in Vandœuvre-lès-Nancy, France
Conditions / Hepatitis c, chronic / Vandœuvre-lès-Nancy, France
Hepatitis c, chronic has been the subject of sustained clinical investigation across multiple research sites.
28 total trials for this combination
Showing top 10 of 28 trials
Trials
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT01168856 | An Observational Study on Long-Term Persistence of Resistant Mutations And Durability of Sustained Virological Response in Patients With Chronic Hepatitis C Treated With Direct Acting Antiviral (DAA)- Containing Regimens | TERMINATED | — |
| NCT01732796 | IFN-free Combination Therapy in HCV-infected Patients Treatment-naive:HCVerso1 | COMPLETED | PHASE3 |
| NCT01271790 | A Study of Response-Guided Duration of Combination Therapy With GS-9451, Pegasys® and Copegus® With and Without Tegobuvir (GS-9190) in Previously Untreated Subjects With Genotype 1 Chronic Hepatitis C | COMPLETED | PHASE2 |
| NCT00517439 | A Study of Hepatitis C Virus (HCV) Polymerase Inhibitor Pro-Drug in Combination With PEGASYS Plus COPEGUS Compared With PEGASYS Plus COPEGUS in Patients With Chronic Hepatitis C Genotype 1 Infection. | COMPLETED | PHASE2 |
| NCT01358864 | Efficacy and Safety of BI 201335 (Faldaprevir) in Combination With Pegylated Interferon-alpha and Ribavirin in Treatment-Experienced Genotype 1 Hepatitis C Infected Patients (STARTverso 3) | COMPLETED | PHASE3 |
| NCT01457768 | A Gilead Sequence Registry of Subjects Who Did Not Achieve Sustained Virologic Response | COMPLETED | — |
| NCT01457755 | Gilead Sustained Virologic Response (SVR) Registry | COMPLETED | — |
| NCT00529568 | Eltrombopag To Initiate And Maintain Interferon Antiviral Treatment To Benefit Subjects With Hepatitis C Liver Disease | COMPLETED | PHASE3 |
| NCT00703118 | A Safety and Effectiveness Study of Telaprevir in Chronic, Genotype 1, Hepatitis C Patients That Failed Previous Standard Treatment | COMPLETED | PHASE3 |
| NCT00077636 | ACCELERATE Study - A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Combination With COPEGUS (Ribavirin) in Interferon-Naive Patients With Chronic Hepatitis C (CHC) Infection. | COMPLETED | PHASE4 |